Welcome to the latest issue of The Krembil.
The Krembil is the official newsletter of the Krembil Research Institute (formerly the Toronto Western Research Institute). Research at Krembil is focused on finding innovative treatments and cures for chronic debilitating disorders, including arthritis and diseases of the brain and eyes.
Stories in this month’s issue include:
● Krembil Research Day 2023: Krembil Research Day showcases the exceptional talent and innovation of trainee researchers.
● Krembil Research Day 2023: Krembil Research Day showcases the exceptional talent and innovation of trainee researchers.
● New Treatment Option: FDA grants full approval to lecanemab, a disease-modifying drug for Alzheimer disease.
● Making a Mark on Depression: Study identifies markers of treatment response in people with major depressive disorder.
● Building Brain Blood Vessels: Study reveals that nucleolin, a brain development protein, becomes reactivated in tumours.
● Decoding Roifman Syndrome: Study provides deep insights into why vision impairments occur in Roifman syndrome.
● Rehabilitation for Vision Loss: Therapy involving visual tasks with auditory feedback effectively treats form of vision loss.
Read these stories here. To read previous issues, see the newsletter archive.